pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
23d
After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce
biospace
23d
Artiva to wind down after two patient deaths in autoimmune cell therapy trials
endpoints
23d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
23d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
23d
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
fiercebiotech
24d
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
biopharma dive
24d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
24d
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
stat
24d
STAT+: Five biotech updates to read after ESMO this weekend
stat
24d
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
stat
24d
A virus that afflicts cows makes the jump to a human
stat
24d
STAT+: NIH’s new vaccine injury center has broad goals beyond RFK Jr.’s focus on shots
stat
24d
STAT+: Moderna CEO on what’s next after success in cancer vaccine
stat
24d
Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listing
fiercebiotech
26d
STAT+: The ESMO presentation everyone’s been waiting for
stat
26d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
27d
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
stat
27d
STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear
stat
27d
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
stat
27d
Q&A: Bristol Myers' Lynelle Hoch on autoimmune CAR-T safety challenges
endpoints
27d
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
biospace
27d
Opinion: It took me 13 years to be diagnosed with MS. Christina Applegate’s misdiagnosis doesn’t surprise me
stat
27d
BMS sheds light on patient death in CAR-T trial, wants to get program back on track
fiercebiotech
27d
Anxiety builds over Medicaid work requirements
stat
27d
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
endpoints
27d
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
biospace
27d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
27d
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
stat
27d
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
27d
Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde
fiercebiotech
← prev
page 6 of 34
next →